Edition:
United Kingdom

Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

45.69USD
21 Aug 2018
Change (% chg)

-- (--)
Prev Close
$45.69
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
292,791
52-wk High
$71.22
52-wk Low
$39.56

Latest Key Developments (Source: Significant Developments)

FDA Approves ARISTADA INITIO For Initiation Of Aristada® For Schizophrenia
Monday, 2 Jul 2018 

July 2 (Reuters) - Alkermes Plc ::FDA APPROVES ARISTADA INITIO™ FOR THE INITIATION OF ARISTADA® FOR SCHIZOPHRENIA.ALKERMES PLC - ARISTADA INITIO IS EXPECTED TO BE AVAILABLE IN MID-JULY.  Full Article

Alkermes Says Receives $50 Million Payment From Biogen
Wednesday, 6 Jun 2018 

June 6 (Reuters) - Alkermes Plc ::ALKERMES RECEIVES $50 MILLION PAYMENT FROM BIOGEN FOLLOWING REVIEW OF PRELIMINARY GASTROINTESTINAL TOLERABILITY DATA FROM THE ONGOING BIIB098 CLINICAL DEVELOPMENT PROGRAM.ALKERMES PLC - ALKERMES EXPECTS TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR BIIB098 TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN Q4 OF 2018.ALKERMES PLC - ALL OF PAYMENT WILL BE RECORDED AS LICENSE REVENUE IN ALKERMES' FINANCIAL RESULTS FOR QUARTER ENDING JUNE 30, 2018.ALKERMES - MAY ALSO RECEIVE $150 MILLION MILESTONE PAYMENT FROM BIOGEN UPON FDA APPROVAL, ON OR BEFORE DEC. 31, 2021, OF NDA FOR BIIB098.  Full Article

Alkermes Q1 GAAP Loss Per Share $0.40
Thursday, 26 Apr 2018 

April 26 (Reuters) - Alkermes Plc ::REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 NON-GAAP LOSS PER SHARE $0.09.Q1 GAAP LOSS PER SHARE $0.40.Q1 REVENUE $225.2 MILLION VERSUS I/B/E/S VIEW $219.3 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.07 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 LOSS PER SHARE $1.35 TO $1.55.COMPANY CONTINUES TO EXPECT TOTAL REVENUES TO RANGE FROM $975 MILLION TO $1.025 BILLION FOR FY18.NOW EXPECTS SG&A EXPENSES TO RANGE FROM $515 MILLION TO $545 MILLION FOR 2018.NOW EXPECTS SHARE-BASED COMPENSATION OF APPROXIMATELY $120 MILLION FOR 2018.COMPANY NOW EXPECTS NON-GAAP BASIC AND DILUTED LOSS PER SHARE OF $0.06 TO A NON-GAAP DILUTED EARNINGS PER SHARE OF $0.12 FY18.CONTINUES TO EXPECT CAPITAL EXPENDITURES TO RANGE FROM $80 MILLION TO $90 MILLION FOR 2018.Q1 EARNINGS PER SHARE VIEW $-0.07, REVENUE VIEW $219.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461
Monday, 16 Apr 2018 

April 16 (Reuters) - Alkermes Plc ::ALKERMES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER.ALKERMES PLC - FDA ACTION EXPECTED BY JAN. 31, 2019.ALKERMES - ALKS 5461 NDA FILING BASED ON RESULTS FROM A CLINICAL EFFICACY AND SAFETY PACKAGE.  Full Article

Primecap Management Co Reports A 11.35 Pct Passive Stake In Alkermes
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Alkermes Plc ::PRIMECAP MANAGEMENT CO REPORTS A 11.35 PCT PASSIVE STAKE IN ALKERMES PLC <<>> AS OF NOV 30 - SEC FILING.  Full Article

Alkermes Expects 2017 Non-GAAP Income Of $0.03 To $0.22/Shr
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Alkermes Plc ::ALKERMES PLC- NOW EXPECTS 2017 TOTAL REVENUES TO RANGE FROM $870 MILLION TO $900 MILLION‍​ - SEC FILING.ALKERMES PLC- NOW EXPECTS 2017 NON-GAAP DILUTED INCOME PER SHARE OF $0.03 TO $0.22.ALKERMES PLC - EXPECTS 2017 GAAP BASIC AND DILUTED LOSS PER SHARE OF $0.91 TO $1.10‍​.  Full Article

Alkermes’ NDA for ARISTADA accepted for filing by U.S. FDA
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Alkermes Plc ::Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® accepted for filing by U.S. FDA.Says FDA issued target action date for Aripiprazole Lauroxil Nanocrystal Dispersion​ NDA of June 30, 2018 under PDUFA.  Full Article

ALKERMES INITIATES CLINICAL STUDY EVALUATING ARISTADA, INVEGA SUSTENNA FOR SCHIZOPHRENIA
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Alkermes Plc :ALKERMES TO INITIATE NEW CLINICAL STUDY EVALUATING ARISTADA® AND INVEGA SUSTENNA® FOR THE TREATMENT OF SCHIZOPHRENIA.ALKERMES PLC - ‍PHASE 3B STUDY WILL ASSESS INVESTIGATIONAL PRODUCT DESIGNED FOR INITIATION ONTO ARISTADA​.ALKERMES PLC - ‍EFFICACY AND SAFETY OF TWO-MONTH ARISTADA COMPARED TO MARKET LEADER INVEGA SUSTENNA WILL ALSO BE EVALUATED IN TRIAL​.  Full Article

ALKERMES PLC REPORTS ‍Q3 GAAP LOSS PER SHARE OF $0.24
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Alkermes Plc ::ALKERMES PLC REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS.‍Q3 TOTAL REVENUES INCREASED 21% YEAR-OVER-YEAR TO $217.4 MILLION​.‍Q3 GAAP LOSS PER SHARE OF $0.24​.‍Q3 NON-GAAP EARNINGS PER SHARE OF $0.03​.‍COMPANY UPDATES FINANCIAL EXPECTATIONS FOR 2017​.Q3 EARNINGS PER SHARE VIEW $-0.01, REVENUE VIEW $231.0 MILLION -- THOMSON REUTERS I/B/E/S.‍NOW EXPECTS 2017 TOTAL REVENUES TO RANGE FROM $850 MILLION TO $880 MILLION​.‍NOW EXPECTS 2017 BASIC AND DILUTED LOSS PER SHARE OF $1.04 TO $1.23​.‍NOW EXPECTS 2017 CAPITAL EXPENDITURES TO RANGE FROM $50 MILLION TO $60 MILLION, REDUCED FROM $70 MILLION TO $80 MILLION​.FY2017 EARNINGS PER SHARE VIEW $-0.04, REVENUE VIEW $894.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Alkermes PLC says ‍initiates rolling submission of ALKS 5461 NDA to U.S. FDA
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Alkermes Plc : :Alkermes PLC- ‍Initiates rolling submission of ALKS 5461 NDA to U.S. FDA; Expects to complete submission of NDA for medicine by year-end 2017​.  Full Article